Proteomic and Immunoblot Analyses of Bartonella Quintana Total Membrane Proteins Identify Antigens Recognized by Sera from Infected Patients by Boonjakuakul, Jenni K. et al.
University of Montana 
ScholarWorks at University of Montana 
Biological Sciences Faculty Publications Biological Sciences 
5-2007 
Proteomic and Immunoblot Analyses of Bartonella Quintana Total 
Membrane Proteins Identify Antigens Recognized by Sera from 
Infected Patients 
Jenni K. Boonjakuakul 
Helen L. Gerns 
Yu-Ting Chen 
Linda D. Hicks 
Michael F. Minnick 
University of Montana - Missoula, mike.minnick@mso.umt.edu 
See next page for additional authors 
Follow this and additional works at: https://scholarworks.umt.edu/biosci_pubs 
 Part of the Biology Commons 
Let us know how access to this document benefits you. 
Recommended Citation 
Boonjakuakul, Jenni K.; Gerns, Helen L.; Chen, Yu-Ting; Hicks, Linda D.; Minnick, Michael F.; Dixon, Scott E.; 
Hall, Steven C.; and Koehler, Jane E., "Proteomic and Immunoblot Analyses of Bartonella Quintana Total 
Membrane Proteins Identify Antigens Recognized by Sera from Infected Patients" (2007). Biological 
Sciences Faculty Publications. 135. 
https://scholarworks.umt.edu/biosci_pubs/135 
This Article is brought to you for free and open access by the Biological Sciences at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Biological Sciences Faculty Publications by an authorized 
administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
Authors 
Jenni K. Boonjakuakul, Helen L. Gerns, Yu-Ting Chen, Linda D. Hicks, Michael F. Minnick, Scott E. Dixon, 
Steven C. Hall, and Jane E. Koehler 
This article is available at ScholarWorks at University of Montana: https://scholarworks.umt.edu/biosci_pubs/135 
INFECTION AND IMMUNITY, May 2007, p. 2548–2561 Vol. 75, No. 5
0019-9567/07/$08.000 doi:10.1128/IAI.01974-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Proteomic and Immunoblot Analyses of Bartonella quintana Total
Membrane Proteins Identify Antigens Recognized by Sera
from Infected Patients
Jenni K. Boonjakuakul,1† Helen L. Gerns,1 Yu-Ting Chen,1 Linda D. Hicks,2
Michael F. Minnick,2 Scott E. Dixon,3 Steven C. Hall,3 and Jane E. Koehler1*
Division of Infectious Diseases, Department of Medicine, University of California at San Francisco, San Francisco,
California 94143-06541; Division of Biological Sciences, University of Montana, Missoula, Montana 598122; and
Biomolecular Resource Center Mass Spectrometry Facility, University of California at San Francisco,
San Francisco, California 941433
Received 15 December 2006/Returned for modification 21 January 2007/Accepted 10 February 2007
Bartonella quintana is a fastidious, gram-negative, rod-shaped bacterium that causes prolonged bacteremia
in immunocompetent humans and severe infections in immunocompromised individuals. We sought to define
the outer membrane subproteome of B. quintana in order to obtain insight into the biology and pathogenesis
of this emerging pathogen and to identify the predominant B. quintana antigens targeted by the human immune
system during infection. We isolated the total membrane proteins of B. quintana and identified 60 proteins by
two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and peptide mass fingerprinting.
Using the newly constructed proteome map, we then utilized two-dimensional immunoblotting with sera from
21 B. quintana-infected patients to identify 24 consistently recognized, immunoreactive B. quintana antigens
that have potential relevance for pathogenesis and diagnosis. Among the outer membrane proteins, the variably
expressed outer membrane protein adhesins (VompA and VompB), peptidyl-prolyl cis-trans-isomerase (PpI),
and hemin-binding protein E (HbpE) were recognized most frequently by sera from patients, which is consis-
tent with surface expression of these virulence factors during human infection.
Bartonella quintana, the agent of trench fever, is a fastidious,
gram-negative, rod-shaped organism that can cause prolonged
bacteremia in immunocompetent humans and severe infec-
tions in immunocompromised individuals. Humans are the
only known reservoir for B. quintana (12), and the vector for
transmission is the human body louse, Pediculus humanus cor-
poris (38). B. quintana infections have occurred worldwide, and
severe, potentially lethal complications, such as endocarditis
and bacillary angiomatosis, can develop in immunocompro-
mised patients with AIDS, cancer, and organ transplants. How-
ever, little is known about the pathogenesis of B. quintana, and
diagnosis of human infection remains extremely challenging.
To address this paucity of knowledge, we sought to identify
potential membrane-associated virulence factors, as well as
protective and diagnostically relevant B. quintana antigens, by
characterizing the total membrane fraction and immunome of
B. quintana.
Bacterial outer membrane proteins (OMP) can be important
virulence factors, playing a critical role in adherence, invasion,
and immune evasion during infection of the host, as well as
during transmission via arthropod vectors. Many outer mem-
brane-associated proteins that are important for pathogenesis
also are consistent targets for the host immune system after
infection. Workers in our lab previously identified a family of
variably expressed outer membrane proteins (Vomp) that play
a role in adhesion and autoaggregation (45). To initially iden-
tify the Vomp family, we used two-dimensional (2D) sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) to visualize changes in expression of membrane pro-
teins in sequential isolates from animals experimentally in-
fected with B. quintana.
To identify additional membrane proteins of B. quintana, we
utilized 2D SDS-PAGE to systematically characterize the total
membrane protein (TMP) subproteome and to determine
whether the Vomp and other identified B. quintana membrane
proteins are recognized by sera from patients naturally in-
fected with B. quintana. We constructed a protein map of the
TMP of B. quintana by 2D gel electrophoresis and then iden-
tified individual proteins by peptide mass fingerprinting
(PMF). We next performed a 2D immunoblot analysis using
sera from 21 B. quintana-infected patients to identify the mem-
brane-associated antigens consistently recognized by the hu-
man immune system during B. quintana infection. Analysis of
these membrane-associated proteins provided insight into the
identities of virulence factors, as well as protective and diag-
nostic antigens, of B. quintana.
MATERIALS AND METHODS
Bacterial strains, growth conditions, and IFA testing. B. quintana strains were
isolated from Bartonella-infected patients with concomitant human immunode-
ficiency virus infections (Table 1) and were passaged fewer than three times from
frozen stocks before use. Strains were streaked onto chocolate agar plates,
incubated at 37°C in candle extinction jars, and harvested for protein preparation
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after 7 days. Bartonella antibody titers were determined for each patient serum
sample by indirect immunofluorescent antibody (IFA) testing. The IFA test for
Bartonella antibodies was developed at the CDC (10, 40). Patient serum was
diluted twofold to 1:1,024, and a reciprocal titer to Bartonella henselae or B.
quintana of 64 was considered a positive result based on previous studies (10,
40). Although the antigenic profile of B. quintana grown with Vero cells for IFA
analysis and the antigenic profile of bacteria grown on agar for immunoblotting
may differ somewhat, culture on agar was necessary to generate a sufficient mass
of bacteria and to maintain bacterial cell fractions that did not contain eukaryotic
cells.
Protein preparation. Subcellular fractions were obtained by using methods
described previously (32, 42). Bacteria were harvested from chocolate agar
plates, washed twice with phosphate-buffered saline (PBS) (pH 7.4), and pelleted
by centrifugation with a tabletop microcentrifuge for 2 to 3 min at 4°C at the
maximum speed. The final pellet was resuspended in 10 mM HEPES buffer. We
added a protease inhibitor cocktail [20 mM 4-(2-aminoethyl)-benzenesulfonyl
fluoride (Calbiochem, San Diego, CA); 1 mg/ml leupeptin, 0.36 mg/ml E-64, and
5.6 mg/ml benzamidine, all obtained from Sigma, St. Louis, MO; 50 mM EDTA]
and incubated the preparation on ice for 10 min. The bacterial cells were
disrupted with five 1-min bursts using a sonicator (Labsonic U sonicator; B.
Braun Biotech, Inc., Allentown, PA) with cooling on ice between bursts. A small
aliquot was removed and saved for whole-cell lysate preparation. Cellular debris
was pelleted by centrifugation at 4,300  g for 30 min at 4°C with a Sorvall
centrifuge (SS-34 rotor; Thermo Electron, Asheville, NC). The supernatant was
transferred to Ultra-Clear ultracentrifuge tubes (13 by 51 mm; Beckman, Palo
Alto, CA) and centrifuged at 100,000  g with an L8-M ultracentrifuge for 1.5 h
at 4°C using an SW55Ti rotor (Beckman). The supernatant was removed and
saved for cytosolic protein preparation. The pellet was resuspended either in 10
mM HEPES for TMP preparation or in 1% (wt/vol) N-lauryl sarcosine (Sigma)
in 10 mM HEPES to separate the OMP. The lauryl sarcosine suspension was
incubated at room temperature for 30 min and then pelleted by ultracentrifu-
gation at 100,000  g for 1.5 h at 4°C. The supernatant containing the inner
membrane proteins (IMP) was saved, and the OMP pellet was resuspended in 10
mM HEPES and treated with nuclease (50 mM MgCl2, 100 mM Tris [pH 7.0],
500 g/ml RNase, 1 mg/ml DNase [Sigma]). OMP were then washed twice in 10
mM HEPES and pelleted by centrifugation at 40,000  g for 30 min at 4°C with
a Sorvall centrifuge (SS-34 rotor). The final TMP preparation was treated with
nuclease and pelleted in the same way. The cytosolic preparation was precipi-
tated with 45% ammonium sulfate (Sigma) in 0.01 M Tris (pH 7.0) and incubated
on ice for 45 min. The precipitated proteins were pelleted by centrifugation at
19,000  g for 30 min at 4°C. The resulting pellet was resuspended in cold PBS
and dialyzed overnight against PBS using a D-tube dialyzer maxi (molecular
weight cutoff, 3,500 Da; Novagen, Darmstadt, Germany). The dialyzed proteins
were concentrated using an Amicon Ultra-4 centrifuge filter (Millipore, Bedford,
MA). The IMP preparation was concentrated in the same way. Protein concen-
trations were determined using a MicroBCA protein assay (Pierce, Rockford,
IL), and proteins were separated by one-dimensional (1D) SDS-PAGE to con-
firm that subcellular fractions were separated. All fractions were frozen at 80°C
until they were used.
2D gel electrophoresis and transblotting. 2D gel electrophoresis was per-
formed using the method of O’Farrell (35) by Kendrick Labs, Inc. (Madison,
WI), as follows. Protein pellets were dissolved in 200 ml of SDS boiling buffer
(5% SDS, 10% glycerol, 60 mM Tris [pH 6.8]) without -mercaptoethanol, and
protein concentrations were determined using a bicinchoninic acid assay
(Pierce). Protein samples were then diluted to obtain a concentration of 2.0 or
4.0 mg/ml in SDS boiling buffer containing 5% -mercaptoethanol and boiled for
5 min. Isoelectric focusing was carried out in glass tubes with an inside diameter
of 2.0 mm using 2% pH 4 to 8 ampholines (BDH; obtained from Hoefer
Scientific Instruments, San Francisco, CA) for 9,600 V  h. For the TMP prep-
arations 100 g of protein was loaded, and for the OMP preparations 200 g was
loaded. After equilibration for 10 min in buffer O (10% glycerol, 50 mM dithio-
threitol, 2.3% SDS, 0.0625 M Tris [pH 6.8]), the tube gels were laid on top of
10% acrylamide slab gels (thickness, 0.75 mm), and SDS slab gel electrophoresis
was carried out for about 4 h at 12.5 mA/gel. The gels were stained with either
Coomassie brilliant blue R-250 or silver stain (34). The Coomassie brilliant
blue-stained gels were maintained wet in 10% acetic acid between sheets of filter
paper until spot excision and subsequent mass spectrometry analysis; the silver-
stained gels were dried between sheets of cellophane. After slab gel electro-
phoresis, a duplicate gel was transblotted onto a polyvinylidene difluoride mem-
brane (Immobilon-P; Millipore).
Immunoblotting of B. quintana membrane proteins with human sera. To
identify immunoreactive proteins in the TMP fraction of B. quintana, proteins
separated by 2D SDS-PAGE were transferred to polyvinylidene difluoride mem-
branes, which were then blocked overnight at 4°C with 5% milk in TBST (150
mM NaCl, 10 mM Tris-HCl [pH 8.0], 0.5% Tween 20, 0.2% sodium azide). The
membranes then were washed three times (5 min each time) in TBST containing
0.5% bovine serum albumin (Sigma) and once in TBST. Patient sera (primary
antibody) were inactivated with 0.5% Nonidet P-40 (Roche, Mannheim, Ger-
many) and diluted 1:50 in TBST. Each membrane was placed in a heat-sealable
bag containing the primary antibody and vigorously shaken for 2 h at room
temperature. The membranes were washed, blocked for 30 min in 1% milk in
TBST, and then washed again. Secondary antibody (alkaline phosphatase-con-
jugated goat anti-human immunoglobulin G; Zymed Laboratories, Inc., South
San Francisco, CA) was diluted 1:5,000 and incubated with the membranes for 30
min at room temperature. The membranes were washed and developed using
alkaline phosphatase buffer (100 mM Tris-HCl [pH 9.5], 100 mM NaCl, 5 mM
MgCl2), nitroblue tetrazolium, and 5-bromo-4-chloro-3-indolylphosphate
(BCIP) (Promega, Madison, WI).
To corroborate the immunoreactivity of B. quintana proteins identified by the
immunoblotting described above, a  genomic expression library of B. quintana
strain JK31 was screened using serum from a Bartonella-infected patient. The
library was generated with a Sau3AI partial digest of B. quintana chromosomal
DNA and the lambda-ZAP Express vector used according to the manufacturer’s
instructions (Stratagene, La Jolla, CA) and was screened by lifting plaques onto
isopropyl--D-thiogalactopyranoside (IPTG)-impregnated nitrocellulose (27),
followed by immunoblotting, as previously described (30). The initial screening
was performed for 3 h at 25°C using polyclonal rabbit anti-B. quintana antiserum
(1:1,000 dilution of serum generated by intravenous immunization with B. quin-
tana, as described previously [43], except that the formalin treatment was omit-
ted). Human antibody recognition of positive plaques was verified by using serum
(1:50 dilution) from a patient with a Bartonella infection; plaque lifts were
probed for 16 h at 25°C. Plaques identified as positive for both human and rabbit
antisera were isolated, replaqued, and rescreened to ensure clonality. Phagemid
contents were excised and rescued with Escherichia coli XLOLR (Stratagene),
and then plasmids were purified and sequenced (29). Data were analyzed using
the Chromas (Technelysium), MacVector (Accelrys, San Diego, CA), and
BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) software. The protein profiles for
each strain were analyzed to identify seroreactive protein species by SDS-PAGE
and immunoblotting, as previously described (27). Molecular mass values for
reactive proteins were cross-referenced to predicted mass values for plasmid-
encoded proteins determined by sequence analysis.
TABLE 1. Reciprocal IFA titers of patient sera
Patient
Bartonella
species
isolated
Source of
B. quintana
isolate
Reciprocal IFA titera
B. quintana B. henselae
1 B. quintana Skin 1,024 256
2 B. quintana Skin 512 256
3 B. quintana Blood 1,024 512
4 B. quintana Skin 1,024 128
5 B. quintana Skin 1,024 31
6 B. quintana Skin 1,024 512
7 B. quintana Skin 1,024 1,024
8 B. quintana Abdominal mass 1,024 256
9 B. quintana Skin 1,024 256
10 B. quintana Skin 1,024 512
11 B. quintana Skin 1,024 1,024
12 B. quintana Skin 256 64
13 B. quintana Blood 8,192 2,048
14 B. quintana Lymph node 512 128
15 B. quintana Blood 512 128
16 B. quintana Blood 2,048 2,048
17 B. quintana Skin 8,192 8,192
18 B. quintana Blood 512 64
19 B. quintana Blood 512 128
20 B. quintana Skin 2,048 128
21 B. quintana Blood 1,024 128
22b None NAc 31 31
23b None NA 31 31
a A reciprocal IFA titer of 64 indicates a positive IFA test (10, 40).
b Control patients 22 and 23 were both culture negative and seronegative.
c NA, not applicable.
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In-gel trypsin digestion. Individual protein spots were excised from the Coo-
massie brilliant blue-stained 2D gels and cut into 1-mm2 pieces. The stain was
removed from the gel pieces by incubating the pieces with 25 mM ammonium
bicarbonate (NH4HCO3) (Sigma) in 50% acetonitrile (Sigma) overnight with
gentle vortexing. After removal of the supernatant, gel pieces were dried with a
SpeedVac and then reduced with 10 mM dithiothreitol (Sigma) for 1 h at 56°C,
followed by alkylation with 55 mM iodoacetamide (Sigma) for 45 min at room
temperature in the dark. Next, the gel pieces were washed with 25 mM
NH4HCO3, dehydrated with 100% acetonitrile and dried with a SpeedVac.
Porcine trypsin (12.5 ng/l in 25 mM NH4HCO3; Promega) was added, and the
gel pieces were allowed to rehydrate for 1 h on ice. The excess trypsin solution
was removed, and 25 mM NH4HCO3 was added to cover the gel pieces. The
preparations were digested at 37°C overnight. Next, the supernatant (postdiges-
tion) was transferred to a clean Eppendorf tube, and tryptic peptides were
extracted from the gel pieces by vortexing them for 15 min with 50% acetonitrile–
50% H2O–0.1% trifluoroacetic acid (Pierce). The peptide extract was combined
with the postdigestion supernatant, and the total volume was reduced to approx-
imately 10 l with a SpeedVac. The concentrated peptide extracts were desalted
using C18 ZipTips (Millipore) and were eluted with 3 to 5 l of 50% acetonitrile–
0.1% trifluoroacetic acid. The peptides were stored at 80°C until they were
used.
Mass spectrometry. PMF was used for protein identification. Peptide extracts
were mixed with a matrix solution containing -cyano-4-hydroxycinnamic acid (2
mg/ml in 50% acetonitrile–0.1% trifluoroacetic acid) at a 1:1 (vol/vol) ratio
directly on a stainless steel target. A matrix-assisted laser desorption ionization—
time of flight mass spectrometry analysis was performed in the reflector, positive-
ion mode in the mass-to-charge ratio (m/z) range from m/z 800 to m/z 4000
utilizing a Voyager DE STR matrix-assisted laser desorption ionization—time of
flight mass spectrometer (Applied Biosystems, Foster City, CA). Each mass
spectrum was calibrated internally using trypsin autolysis product masses. Mass
spectra were processed (baseline adjustment, noise filtering, and de-isotoping) to
produce a list of monoisotopic, monoprotonated molecular ion masses. Mo-
noisotopic peak lists were submitted to the Mascot Peptide Mass Fingerprint
(http://www.matrixscience.com) search engine for analysis. Searches that inter-
rogated the Eubacteria protein database within the MSDB (ftp://ftp.ncbi.nih.gov
/repository/MSDB/msdb.nam) sequence database were performed. Validation of
the results was based on the top hit score, a requirement for high precision of
mass measurement (defined as a low standard deviation, 	25 ppm, of mass
assignment errors for all matching peptide masses detected within a sample spot)
and a minimum of 30% sequence coverage.
Selected protein identities were confirmed by high-performance liquid chro-
matography-tandem mass spectrometry. Liquid chromatographic separation was
performed with an Ultimate capillary high-performance liquid chromatography
system (Dionex/LC Packings, Sunnyvale, CA) equipped with a PepMap trap
column (Dionex/LC Packings) and a reversed-phase C18 nanocolumn (packed in
house; inside diameter,75 m; length, 15 cm; pore size, 100 Å; particle size, 3
m) and a Famos Micro autosampler. A 3- to 4-l aliquot of peptide extract was
loaded onto the trap column with loading solvent (0.1% formic acid) at a flow
rate of 20 l/min. The trap column was washed with the loading solvent for 3 min
before it was switched in line with the reversed-phase nanocolumn. The nano-
column mobile phase flow rate was 325 nl/min, and the nanocolumn was main-
tained at the ambient temperature. The nanocolumn was equilibrated with 2%
solvent B (80% acetonitrile, 20% H2O, 0.08% formic acid) and 98% solvent A
(2% acetonitrile, 98% H2O, 0.1% formic acid) for 20 min prior to sample
injection. Peptides were separated using a binary gradient that consisted of a
5-min isocratic wash with 2% solvent B, followed by a linear gradient from 2%
solvent B to 50% solvent B over 45 min and then by a column cleanup step
consisting of 95% solvent B for 7 min. The column effluent flowed directly into
a nanoelectrospray ion source (Protana, Odense, Denmark) in a QSTAR XL
quadrupole/quadrupole time of flight mass spectrometer (Applied Biosystems).
Proteins were identified by isolating sequentially eluting peptide populations
with a single m/z value in the mass spectrometer, fragmenting each population,
and determining the masses of the peptide fragment ions. The experimentally
determined peptide fragment ion masses were matched, within a window of 
0.2
Da, to theoretical fragment ion masses generated by in silico fragmentation of all
theoretical tryptic peptides derived from Eubacteria protein sequences in the
MSDB database.
In silico analysis of proteins that were identified. In addition to spot identi-
fication by PMF, we used PSORTb v.2.0 to predict protein localization based on
signal peptides, transmembrane helices, homology to proteins whose localization
is known, and amino acid composition and motifs (14; http://www.psort.org
/psortb/). Identities of protein families were determined using Pfam (4, 11;
http://www.sanger.ac.uk/Software/Pfam/). Grand average of hydropathy was used
to evaluate the hydrophilicity and hydrophobicity of each protein along its amino
acid sequence (23; http://us.expasy.org/tools/protparam.html).
Evaluation of gels and immunoblots. Spot detection for gels and blots was
performed using the 2D Evolution software (Nonlinear Dynamics, Durham,
NC). Spot detection for the master gel was performed manually due to nonspe-
cific spot detection. A silver-stained gel of B. quintana JK31 proteins was used as
the master protein profile, and each spot was assigned a number. Immunoreac-
tive spots identified on the blots were automatically matched with the master gel,
and additional spots detected visually were added manually. To allow compari-
sons across immunoblots, the background was subtracted using a fully automated
method with the Evolution software, called Lowest on Boundary, and was de-
termined by tracing a line just outside the boundary of each spot and then using
the lowest pixel intensity that was encountered during this process as the back-
ground intensity for that spot. Additionally, each blot was normalized to a single
common spot in the blot to eliminate differences in spot intensity due to immu-
noblot development. The volume of each spot was then calculated by dividing the
pixel intensity by the area of the spot. Means, medians, and ranges of volumes
were determined.
RESULTS
Enrichment and separation of B. quintana membrane pro-
teins resulted in identification of distinct membrane fractions
by 1D and 2D SDS-PAGE. OMP were isolated from B. quin-
tana JK31 using lauryl sarcosine fractionation. This method
has been used to enrich OMP from a number of bacterial
species (3, 31, 39) and was also utilized to separate the OMP
from the IMP of B. henselae (42). We initially compared the
protein profiles of the subcellular fractions of B. quintana after
separation by 1D SDS-PAGE, followed by Coomassie blue
staining (Fig. 1). Enrichment of the OMP and IMP from the
TMP preparation was evident when the proteins were com-
pared with proteins from the cytosolic preparation. There were
prominent bands in the OMP preparation at approximately
116, 93, 45, 40, and 34 kDa (Fig. 1). These prominent OMP
bands either were observed exclusively with the OMP fraction
or were highly enriched in the OMP fraction compared with
the IMP fraction. Coomassie blue staining of proteins sepa-
FIG. 1. Subcellular fractions of proteins from B. quintana wild-type
strain JK31 visualized on a Coomassie blue-stained 1D SDS-PAGE
gel. Proteins were fractionated using a lauryl sarcosine method, sepa-
rated on a 10% acrylamide gel, and stained with Coomassie blue. The
following subcellular fractions were loaded in individual lanes: whole-
cell lysate (WCL), cytoplasmic fraction (CYT), TMP, sarcosine-insol-
uble OMP, and sarcosine-soluble IMP. Distinct protein profiles of the
fractions can be distinguished, and the prominent bands in the OMP
preparation are indicated by asterisks. The positions of molecular
weight markers (lane MW) are indicated on the right.
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rated on a gel containing a lower percentage of acrylamide
revealed that the 116-kDa bands in the OMP and IMP frac-
tions were actually at slightly different molecular masses (data
not shown).
Mass spectrometry analysis identified distinct proteins that
comprise the TMP subproteome of B. quintana. The TMP and
OMP preparations were resolved by 2D SDS-PAGE, followed
by silver staining. The resolution of individual spots from gel to
gel and for different protein preparations was highly reproduc-
ible. We visualized more than 300 distinct protein spots in the
TMP preparation in a pI range from 4.5 to 9.5 and in a mo-
lecular mass range from 14 to 220 kDa (Fig. 2). Protein spots
were numbered, excised from Coomassie blue-stained gels,
subjected to in-gel tryptic digestion, and submitted for protein
identification by PMF. We excised 137 spots and identified 110
separate protein spots (Table 2). Some spots were not posi-
tively identified because of the low concentration of protein
and/or contamination with human keratin. The 110 spots iden-
tified by PMF correspond to 60 B. quintana genes. With the
exception of a few spots that stained intensely with silver stain
but not with Coomassie blue, most protein spots that were
visualized were identified.
A number of the B. quintana membrane proteins identified
appeared as protein isoforms or families. The protein product
of a single gene can appear as several protein spots on a 2D gel
due to posttranslational modifications; these isoforms are usu-
ally visualized as a horizontal pattern of spots at the same
molecular weight. The modifications of bacterial proteins can
include phosphorylation, glycosylation, methylation, deamida-
tion, and biotinylation, each of which can affect the charge and
the isoelectric point. Of the 60 unique proteins that we iden-
tified, 18 had at least two isoforms, and these proteins included
proteins that play a role in energy metabolism (AcnA, AtpA,
AtpD, PpdK, SucB, and SucD), protein fate (ClpB and
MopA), protein synthesis (FusA, RpsA, and Tuf1), transcrip-
tion (Pnp and Rho), purine ribonucleotide synthesis (GuaB
and GlyA), and virulence (HbpE, HbpD, VompA, VompB,
and VompC).
FIG. 2. 2D map of the total membrane subproteome of B. quintana wild-type strain JK31. Membrane proteins were separated by isoelectric
point in the first dimension and then by molecular mass in the second dimension. Proteins were visualized by silver staining, and spots were excised
individually and then identified by PMF. Nearly 300 protein spots were visualized, and 110 proteins, representing 60 unique B. quintana proteins,
were identified by PMF. Each JB number indicates a protein for which a PMF identity was obtained; these numbers correspond to the protein
identities shown in Table 2, Table 3, and Table 4. The arrowhead on the left indicates an internal standard, tropomyosin, which was included with
each sample. This standard migrated as a doublet with a molecular mass of 33 kDa and a pI of 5.2 (for the lower spot). The positions of molecular
weight markers are indicated on the right, and pI values are indicated at the bottom.
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Twenty-four percent (26/110) of the proteins identified were
predicted by PSORTb to localize to the outer membrane, 65%
(72/110) of the proteins were predicted to localize to the cy-
toplasm, and the localizations of 11% (12/110) of the proteins
are not known. The 26 proteins localized to the outer mem-
brane correspond to 10 distinct gene products, including three
hemin-binding proteins (HbpA, HbpD, and HbpE), Omp43,
Omp89, peptidyl-prolyl cis-trans-isomerase (Ppi), BQ08370 (a
putative OMP), and three adhesins (VompA, VompB, and
VompC). The spots with the greatest apparent protein con-
centration correspond to GroEL (MopA) (at 57.6 kDa; spots
JB51, JB52, JB74, JB78, JB109, and JB121), EF-Tu (Tuf1) (at
42.9 kDa; spots JB1/108, JB37, JB38, JB79, and JB115), HbpA
(at 29.3 kDa; spot JB87), HbpD (at 32.7 kDa; spots JB2,
JB3/31, JB30, JB88, JB119, and JB137), HbpE (at 33 kDa;
spots JB4/107, JB5/113, and JB114), VompA (97.0 kDa),
VompB (100.5 kDa), and VompC (99.8 kDa). Pfam predic-
tions and grand average of hydropathy values for all of the
spots identified are shown in Tables 2 and 3.
Immunoblotting with human sera identified 24 immunore-
active B. quintana membrane proteins. We identified 24 B.
quintana proteins that are recognized consistently by sera from
humans with documented B. quintana infections. TMP from
the same preparation that was used for PMF were separated
simultaneously by 2D SDS-PAGE to produce two identical 2D
gels, and then TMP from one gel were transferred and immu-
noblotted with sera from each of 21 patients from whom B.
quintana was isolated and whose sera were positive for Bar-
tonella antibodies as determined by IFA analysis (10, 40) (Ta-
ble 1). Each patient’s serum was analyzed on a separate im-
munoblot, and immunoreactive antigens were identified by
alignment with a simultaneously prepared silver-stained gel
using the 2D Evolution software (Nonlinear Dynamics). For
negative controls, two blots with 2D-separated TMP were im-
munoblotted with sera that were from Bartonella IFA-negative,
culture-negative patients. These control sera detected a few B.
quintana proteins, usually the protein spots that had the high-
est protein concentrations and were most dense. The proteins
that were immunoreactive on these two negative control blots
were considered false positives and were not included in the
analysis of positive sera.
To identify the B. quintana antigens most commonly recog-
nized by sera from patients infected with B. quintana, we es-
tablished a positive cutoff value of 24, representing the B.
quintana TMP antigens recognized by sera from 24% or more
of the patients infected with B. quintana (at least 5 of the 21
patients analyzed). Using this cutoff value, we identified 24
immunodominant B. quintana proteins recognized by sera
from these patients (Table 4). Figure 3 shows a representative
2D immunoblot of B. quintana TMP probed with serum from
patient 4 (Table 1). The pI values of these immunoreactive
antigens ranged from 4 to 7, and the predicted molecular
masses ranged from 20 to 100 kDa. Four of the immunodom-
inant antigens were OMP (VompA, VompB, HbpE, and Ppi).
The remainder were predicted to be cytoplasmic proteins, and
many of these cytoplasmic proteins have been identified pre-
viously in the outer membrane fractions of other gram-nega-
tive organisms, including other Bartonella species (6, 16, 42).
Each of the 24 immunoreactive antigens commonly recognized
by patients’ sera was labeled in the immunoblot shown in Fig.JB
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3. Note that the serum from B. quintana-infected patient 4
recognized all of the 24 immunoreactive proteins whose values
were above the 24% cutoff value for all patients. Antibodies in
the serum of patient 4 also recognized several B. quintana
protein spots whose values were below the cutoff value of 24%;
therefore, although these proteins (e.g., NusA, VompC, CarB,
SecA, SdhA, and PdhB) were strongly immunoreactive on the
blot, they were not labeled or included in Table 4. Note that in
some cases (e.g., GroEL [MopA], AtpA, EF-Tu [Tuf1], RpsA,
HbpE, and Pnp), the most dominant member of a protein
family did not meet the inclusion criteria because the spot was
so highly concentrated that it was also immunoreactive with
the negative sera. Therefore, these proteins were not included
in the analysis.
Spots JB15 and JB17 had low sequence coverage as deter-
mined by PMF, and spot JB16 had no significant hits in the
database search but was found to have monoisotopic peaks
similar to those of spots JB15 and JB17. Because these proteins
were found to be highly immunogenic, we confirmed their
identities by submitting the peptides for mass spectrometry/
mass spectrometry analysis. Validation of the liquid chroma-
tography-mass spectrometry/mass spectrometry results con-
firmed that these three protein spots (spots JB15, JB16, and
JB17) were dihydrolipoamide succinyltransferase (SucB) from
B. quintana.
In addition to the immunoblot analysis, screening of an
expression library was performed to identify antigenic proteins
using a  phage genomic library of B. quintana JK31. The
primary screen included 3,000 plaques per plate and four
plates (a total of 12,000 plaques). Twelve plaques were iden-
tified as plaques that were reactive with human and rabbit
antisera, and they were replaqued and rescreened to ensure
clonality. Characterization of two positive clones resulted in
identification of SucB and GroEL (MopA), confirming the
immunoreactivities of these two proteins observed by immu-
noblot analysis.
DISCUSSION
The outer membrane of a bacterium forms the interface
between the microorganism and the host and plays an essential
role in adhesion and host immune evasion, two important
virulence mechanisms utilized by B. quintana. The bacterial
proteins mediating these interactions between B. quintana and
its host are critical targets of the host immune response and
often have diagnostic relevance, and they are useful candidate
antigens for vaccine development. Our goals were to charac-
terize the TMP subproteome of B. quintana and to further
identify the immunome subset of proteins recognized by sera
from humans infected with B. quintana. The membrane pro-
teins that we identified are involved in pathogenesis and also
are candidate antigens for diagnostic evaluation, treatment,
and prevention of B. quintana infection, especially in patients
with concomitant human immunodeficiency virus infections.
2D mapping of the B. quintana TMP fraction by PMF iden-
tified 60 individual proteins. One-quarter of the proteins that
TABLE 3. B. quintana proteins identified in this study and predicted to be localized to the outer membrane by PSORTba
Gene Spot TIGR protein description
Predicted
mol wt
(103)
Predicted
pI
% Sequence
coverage
PSORTb
probability Pfam model
Pfam
E-value
GRAVY
valueb
hbpA JB87 Hemin-binding protein A 29.3 9.5 43 9.45 Porin 2.70E-05 0.119
hbpD JB2 Hemin-binding protein D 32.7 9.0 21 10.00 Transmembrane domain 0.0033 0.247
hbpD JB3 (JB31)c Hemin-binding protein D 32.7 9.0 19 (35) 10.00 Transmembrane domain 0.0033 0.247
hbpD JB30 Hemin-binding protein D 32.7 9.0 40 10.00 Transmembrane domain 0.0033 0.247
hbpD JB88 Hemin-binding protein D 32.7 9.0 29 10.00 Transmembrane domain 0.0033 0.247
hbpD JB119 Hemin-binding protein D 32.7 9.0 43 10.00 Transmembrane domain 0.0033 0.247
hbpE JB4 (JB107)c Hemin-binding protein E 33.0 4.9 37 (33) 9.93 Porin 0.014 0.190
hbpE JB5 (JB113)c Hemin-binding protein E 33.0 4.9 31 (47) 9.93 Porin 0.014 0.190
hbpE JB84 Hemin-binding protein E 33.0 4.9 30 9.93 Porin 0.014 0.190
hbpE JB114 Hemin-binding protein E 33.0 4.9 29 9.93 Porin 0.014 0.190
ppi JB33 Peptidyl-prolyl cis-trans-isomerase 35.7 5.6 68 9.92 Rotamase 1.20E-38 0.415
ppi JB35 Peptidyl-prolyl cis-trans-isomerase 35.7 5.6 57 9.92 Rotamase 1.20E-38 0.415
omp43 JB42 (JB91)c Outer membrane protein 44.0 9.5 50 (55) 9.93 Porin 1.80E-51 0.291
omp43 JB124 Outer membrane protein 44.0 9.5 66 9.93 Porin 1.80E-51 0.291
BQ08370 Outer membrane protein 48.4 9.9 52 10.00 Outer membrane efflux
protein
3.70E-32 0.096
omp89 JB106 (JB126)c Outer membrane protein 88.8 9.3 41 (46) 10.00 Surface antigen 1.80E-79 0.261
vompA JB75 Variable outer membrane protein 101.2 5.0 29 10.00 Hemagglutinin 8.40E-06 0.387
vompB Variable outer membrane protein 108.8 5.0 29 8.97 Hemagglutinin 8.40E-06 0.372
badA3 Surface protein/Bartonella adhesin 104.2 5.2 21 9.52 Hemagglutinin 8.20E-06 0.372
vompA JB77 Variable outer membrane protein 101.2 5.0 41 10.00 Hemagglutinin 8.40E-06 0.387
vompC Variable outer membrane protein 104.3 5.2 41 9.52 Hemagglutinin 8.40E-06 0.383
badA2 Variable outer membrane protein 101.3 4.8 41 10.00 Hemagglutinin 8.40E-06 0.393
badA3 Surface protein/Bartonella adhesin 104.2 5.2 39 9.52 Hemagglutinin 8.20E-06 0.372
vompB Variable outer membrane protein 108.8 5.0 38 8.97 Hemagglutinin 8.40E-06 0.372
vompA JB116 Variable outer membrane protein 101.2 5.0 33 10.00 Hemagglutinin 8.40E-06 0.387
badA2 Variable outer membrane protein 101.3 4.8 31 10.00 Hemagglutinin 8.40E-06 0.393
vompC Variable outer membrane protein 104.3 5.2 31 9.52 Hemagglutinin 8.40E-06 0.383
badA3 Surface protein/Bartonella adhesin 104.2 5.2 28 9.52 Hemagglutinin 8.20E-06 0.372
vompA JB120 Variable outer membrane protein 101.2 5.0 39 10.00 Hemagglutinin 8.40E-06 0.387
badA3 JB123 Surface protein/Bartonella adhesin 104.2 5.2 34 9.52 Hemagglutinin 8.20E-06 0.372
vompC Variable outer membrane protein 104.3 5.2 33 9.52 Hemagglutinin 8.40E-06 0.383
vompB JB117 Variable outer membrane protein 108.8 5.0 38 8.97 Hemagglutinin 8.40E-06 0.372
a Twenty-one spots representing 10 genes were analyzed.
b GRAVY, grand average of hydropathy.
c Some protein spots were identified by PMF more than once: the numbers in parentheses are the spot numbers for the duplicate proteins.
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we identified are predicted to be membrane proteins, nearly
one-third of the proteins are predicted to be cytoplasmic pro-
teins, and the remainder have unknown localizations. As found
in other gram-negative bacteria (6, 16), including B. henselae
(42), many of the proteins that fractionated with the TMP
fraction are not membrane proteins. We performed a search of
the B. quintana genome in the TIGR database for “membrane
proteins” and identified 55 membrane-associated proteins. Of
these 55 proteins, 61.8% were found to have a predicted pI of
9.0 or higher. With our 2D gel system, we were able to
resolve proteins with pI values ranging from 4.5 to 9.5, and
therefore we identified only a few OMP with a pI near 9.5,
including Omp43 (pI 9.5), Omp89 (pI 9.3), and HbpA (pI 9.5).
Identification of the more basic membrane proteins in the pI
range from 9.0 to 12.0 requires a different method to improve
resolution, and indeed, these very basic membrane proteins of
gram-negative bacteria are often refractory to fractionation
regardless of the method used (42).
Of the cytosolic proteins that fractionated in the 2D TMP
fraction, GroEL (MopA) and EF-Tu (Tuf1) are commonly
found in membrane preparations of other gram-negative bac-
teria (2, 41). Two of the proteins that we identified, GroEL and
DnaK, are common heat shock proteins that also function as
chaperones and thus are often membrane associated (7, 37).
Indeed, Bartonella bacilliformis has been shown to actively se-
crete GroEL (30). Other cytosolic proteins, including FusA,
TypA, EF-Tu, and Tig, are ribosome-associated proteins that
can be membrane associated during the biosynthesis of pro-
teins destined for the periplasm or outer membrane (17). Ad-
ditional cytoplasmic proteins are associated with the mem-
brane either transiently or while they are functioning as
chaperones (7), and thus our detection of these proteins in the
membrane fraction is not unexpected or unprecedented.
Comparison of the OMP subproteomes of B. henselae and B.
quintana identified the Vomp as unique to B. quintana. By
using 2D SDS-PAGE, we identified 19 membrane proteins
that were present in both B. quintana and B. henselae (42),
another species of Bartonella that infects AIDS patients. Of the
TABLE 4. B. quintana proteins found to be immunoreactive with sera from patients infected with Bartonella
Spot Gene Protein description % of patientsreactivea
Vol of spotb
Mean Median Range
OMP
VompB vompB Variable outer membrane protein B 33 26.0 20.4 5.6–97.1
VompA vompA Variable outer membrane protein A 29 31.5 22.3 6.0–120.2
JB33 ppi Peptidyl-prolyl cis-trans-isomerase 29 8.4 7.5 2.2–17.8
JB114 hbpE Hemin-binding protein E 24 5.2 3.8 1.3–12.5
Non-OMP
JB16 sucB Dihydrolipoamide succinyltransferase 76 34.0 21.2 3.1–146.8
JB17 sucB Dihydrolipoamide succinyltransferase 76 17.6 9.9 0.5–89.4
JB15 sucB Dihydrolipoamide succinyltransferase 52 20.3 9.8 2.4–101.5
JB12 guaB Inosine-5-monophosphate dehydrogenase 52 11.8 7.5 2.3–51.2
JB38 tuf1 Elongation factor tu 48 7.9 6.1 3.1–18.1
JB51 mopA Chaperonin protein GroEL 48 19.3 13.9 2.3–62.5
JB52 mopA Chaperonin protein GroEL 48 24.1 19.8 1.9–104.0
JB74 mopA Chaperonin protein GroEL 48 9.0 6.5 1.7–29.0
JB14 atpD ATP synthase beta chain 43 15.6 8.8 3.7–50.0
JB37 tuf1 Elongation factor tu 43 10.4 7.5 1.7–47.4
JB79 tuf1 Elongation factor tu 43 13.8 10.6 2.3–69.3
JB10 rplY 50S ribosomal protein L25 38 31.5 22.9 4.6–87.9
JB11 sucD Succinyl-coenzyme A synthetase alpha chain 38 8.5 7.3 4.1–16.2
JB19 rpsA 30S ribosomal protein s1 38 5.8 5.5 0.7–11.3
JB65 ppdK Pyruvate phosphate kinase 38 4.4 3.0 0.7–15.2
JB9 Hypothetical protein 33 15.2 10.1 4.5–44.6
JB21 rpsA 30S ribosomal protein s1 33 9.5 5.2 1.2–53.5
JB47 atpD ATP synthase beta chain 33 10.6 7.5 4.3–30.2
JB55 dnaK Heat shock protein 70 DnaK 33 28.2 27.2 6.6–72.7
JB109 mopA Chaperonin protein GroEL 33 51.8 39.2 3.5–217.7
JB25 ibpA2 Small heat shock protein 29 8.3 6.8 2.3–15.1
JB29 purC Phosphoribosylaminoimidazole-
succinocarboxamide synthase
29 4.7 3.8 1.9–8.7
JB45 atpA ATP synthase alpha chain 29 5.6 3.4 1.6–13.3
JB56 ftsZ Cell division protein FtsZ homolog 29 5.7 4.6 1.5–13.8
JB57 typA GTP-binding protein TypA 29 4.3 4.0 2.7–6.9
JB63 pnp Polyribonucleotide nucleotidyltransferase 29 4.1 4.3 1.1–7.1
JB18 rho Transcription terminator factor rho 24 6.0 4.5 0.3–15.5
JB44 atpA ATP synthase alpha chain 24 5.0 3.3 2.5–11.0
JB50 tig Trigger factor 24 16.7 6.4 1.9–57.9
JB73 guaB Inosine-5-monophosphate dehydrogenase 24 7.2 3.4 2.7–20.1
JB121 mopA Chaperonin protein GroEL 24 4.0 2.7 1.5–7.2
JB133 ABC transporter, ATP-binding protein 24 4.1 3.3 0.8–8.9
a Percentage of patient sera found to have immunoreactivity to the protein of the total number of patients (n  21).
b The volume of a spot was determined by dividing the pixel intensity by the area of the spot (2D Evolution Analysis software; Nonlinear Dynamics, Durham, NC).
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60 unique membrane-associated B. quintana proteins, 13 have
characteristics of a prototypical OMP as determined by
PSORTb analysis: HbpA, HbpD, HbpE, Omp43, Omp89, Ppi,
BQ08370, and six Vomp paralogs. Five of the OMP identified
in B. quintana have orthologs that also were identified in the
sarcosine-insoluble fraction of B. henselae (42): HbpA, HbpD,
Omp43, Omp89, and Ppi. Two additional OMP were identified
in B. henselae but not in B. quintana: HutA and BH00450.
Although the latter two OMP are present in the B. quintana
genome, they have predicted pI values of 9.5 and 9.9, respec-
tively, and did not resolve well in our system.
Finally, our subproteome analysis identified the following
OMP virulence factors that were unique to B. quintana and
were not found in B. henselae (42): VompA, VompB, VompC,
and six additional isoforms of Vomp (spots JB75, JB77, JB116,
JB117, JB120, and JB123), in addition to HbpE (spots JB4/107,
JB5/113, and JB114) (Fig. 2). The vomp genes encode a family
of four OMP adhesins that contribute to binding of B. quintana
to collagen and to autoaggregation (45). The Vomp proteins
are members of the newly described trimeric autotransporter
adhesin family that includes YadA of Yersinia enterocolitica (9).
Each Vomp has a major variable region near the adhesin tip.
The major variable region of each Vomp confers a specific and
different virulence phenotype on B. quintana (e.g., VompA is
necessary and sufficient to mediate autoaggregation). In addi-
tion, in a recent study Schulte et al. (44) suggested a specific
role for B. quintana Vomp in the angiogenic reprogramming of
host cells. Infection of human macrophages (THP-1) and ep-
ithelial cells (HeLa 229) with B. quintana JK31 (a Vomp-
expressing strain) induced secretion of vascular endothelial
growth factor from both cell types. Strains lacking Vomp ex-
pression (BQ2-D70, B. quintana Toulouse, and B. quintana
Munich) did not induce secretion of vascular endothelial
growth factor (44). This suggests that the Vomp proteins have
a specific pathogenic role in the angiogenesis response that
occurs in bacillary angiomatosis lesions.
Five hemin-binding proteins (Hbp) have been described in
B. quintana (HbpA to HbpE) (29) and are encoded by a five-
member gene family comprised of hbpA to hbpE (29). Five
orthologs also occur in B. henselae (HbpA to HbpD and
Bh10780) (1). We identified three B. quintana Hbp by PMF:
HbpA (spot JB87), HbpD (spots JB2, JB3/31, JB30, JB88, and
FIG. 3. 2D immunoblot of TMP from B. quintana JK31 probed with serum from a B. quintana-infected human. 2D separation of the TMP
fraction was performed, and the proteins were transferred and immunoblotted with a 1:50 dilution of serum from patient 4, who had a documented
B. quintana infection. Antibodies from this patient bound all of the antigens which were identified as antigens that were consistently recognized
by sera from the 21 patients tested (immunodominant antigens are shown in Table 4). A total of 24 immunodominant antigens were identified;
their isoelectric points ranged from 4 to 7, and their molecular masses ranged from 20 to 100 kDa. The positions of molecular weight markers
(MW) are indicated on the right, and the pI values are indicated at the bottom.
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JB119), and HbpE (spots JB4/107, JB5/113, JB84, and JB114)
(Fig. 2 and Table 2). Because heme is essential for B. quintana
(33), it is not surprising to find that Hbp are very abundant
OMP. Recent studies have shown that the hbp gene family
exhibits differential expression in response to environmental
cues such as temperature, oxygen, and heme concentration (5),
and the hbpADE subfamily is markedly induced under condi-
tions that simulate the conditions in the human host. HbpA,
HbpD, and HbpE are the most prominent Hbp, and although
this is in agreement with previous reports regarding hbp gene
induction, the pI values of HbpB and HbpC (10.2 and 10.1,
respectively) are higher than the highest pI resolved by our
system (pI 9.5).
TMP virulence factors, including Vomp and Hbp family
members, are highly immunogenic during human B. quintana
infection. We identified 24 B. quintana proteins that are con-
sistently recognized by sera from patients infected with B.
quintana, using the 2D Evolution software to identify immu-
noreactive spots, and evaluated spot size relative to intensity.
Of these 24 proteins, 4 were proteins that that we identified in
this study as OMP: VompA, VompB, HbpE, and Ppi (Table 4
and Fig. 3). Twenty are cytosolic proteins or IMP that also are
recognized by sera from patients infected with B. quintana.
OMP and non-OMP are listed in Table 4 in order of frequency
of recognition by human serum.
Of the four immunoreactive OMP that we identified by PMF
that are consistently immunoreactive with patient sera, three
are known virulence factors: VompA, VompB, and HbpE. The
Vomp adhesins are of particular interest because they are
unique to B. quintana and they play a significant role in viru-
lence during infection (45). Bartonella species can survive in
the bloodstream for weeks and even months and can adhere to
host cell erythrocytes. We demonstrated that the Vomp are
surface exposed, using binding of fluorescent antibodies. We
found that some vomp genes undergo phase variation in vivo
and are not expressed during prolonged bloodstream infection
(45). It is advantageous for the bacterium to be able to alter the
expression of the Vomp adhesins and other virulence-associ-
ated factors in order to evade the host immune response. It is
therefore noteworthy that the surface-expressed Vomp ad-
hesins are targeted by the human immune system in many
patients infected with B. quintana, which could be important in
generating phase and/or antigenic variation of the vomp gene
expression in this bacterium. VompC was not recognized by a
sufficient number of patients, however, and thus did not meet
the criteria for inclusion. It is therefore possible that not all B.
quintana isolates express all four Vomp proteins, preventing
targeting of the Vomp proteins by the host immune system.
The lack of antibodies recognizing VompC could be the result
of attenuated expression of VompC compared to the expres-
sion of VompA and VompB; VompC also may not be compa-
rably immunogenic. Finally, VompC expression could be
turned off due to phase variation, before antibodies are elicited
in the host. It will be interesting to examine the isolates from
the patients whose sera recognized only one or two of the four
Vomp proteins to see if a corresponding isolate from a patient
has the full complement of four vomp genes and, if so, whether
the genes are expressed. We used a single strain, B. quintana
JK31, for antigen preparation, against which we blotted each
patient’s serum. This enabled us to directly compare the anti-
body responses of the patients and to determine which anti-
gens are most consistently recognized. However, it is possible
that JK31 does not have the same protein profile as the B.
quintana strain from an individual patient, and this should be
investigated further. For instance, from the standpoint of both
virulence and diagnosis, it is important to determine if one
specific Vomp is always expressed during human infection with
B. quintana.
HbpE was the only other OMP that was identified as a
protein that was immunoreactive with at least 24% of the
patient sera. Although differences in gene expression have
been noted for hbpE (5), more notable is the level of immu-
nogenicity of the HbpE protein compared to the levels of
immunogenicity of other members of the Hbp gene family. It
should be interesting to further evaluate differences in this
protein and to determine the specific role of HbpE in Bar-
tonella pathogenesis.
Characterized B. quintana immunome includes antigens
that have potential diagnostic and vaccine utility. One of our
goals was to identify relevant B. quintana antigens recognized
by the human immune response during the natural course of
infection which could lead to both improved diagnosis and an
understanding of Bartonella infections. Antibody detection is
the most widely used diagnostic test for B. quintana infection;
an IFA test is the current reference method. However, IFA
tests are performed in only a few laboratories, and the Bar-
tonella IFA test is subjective and extremely laborious. Antigen
must be prepared by cocultivation of Bartonella with Vero cells
on slides, the serum must be serially diluted, and the assay
results must be manually screened and graded by highly
trained personnel. In addition to the difficulty in performing
the IFA test, cross-reactions with other Bartonella species can
occur. As shown in Table 1, it is apparent that the IFA titers
for both B. henselae and B. quintana are positive in nearly all
patients with a documented B. quintana infection, and in some
cases the titers for the two species are nearly the same, pre-
venting identification of the infecting Bartonella strain to the
species level. In addition, cross-reactivity can occur with Cox-
iella burnetii and Chlamydia species (25, 28). Culture-based
diagnosis of Bartonella infection is even more difficult and
time-consuming (21, 24), and molecular biology techniques
have little practical application outside the research lab. In
most of the immunoscreens for diagnostic antigens in Bar-
tonella workers have used pooled sera from a small number of
patients without culture-proven infections or sera collected
from experimentally infected small animals (8, 13).
In this study, we utilized a large collection of sera from B.
quintana culture-positive humans in conjunction with 2D SDS-
PAGE and PMF subproteome data for a virulent strain to
systematically characterize the total membrane immunome of
B. quintana, and we identified proteins that are recognized
during human infection. All 21 patients had naturally acquired
B. quintana infections, as documented by isolation of the bac-
terium from blood or tissue or both (21, 22) and by positive
reciprocal IFA titers for B. quintana of 64 (10, 40) (Table 1).
Using these sera, 44 immunoreactive B. quintana TMP were
identified by 2D immunoblot analysis. In addition to these
immunodominant TMP, we also found 20 non-TMP that were
reactive with one-quarter of the patient sera. We found that
SucB (spots JB15, JB16, and JB17) had the highest frequency
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of recognition, and we also identified SucB by immunoscreen-
ing of an expression library. SucB (dihydrolipoamide succinyl-
transferase), a 43.8-kDa cytosolic protein, was recognized by
76% of our patient sera (Table 4) and has been detected in
immunoscreens of genomic expression libraries for both B.
henselae and Bartonella vinsonii subsp. berkhoffii (15, 18, 26).
Another cytosolic protein, the 63.8-kDa protein FtsZ (spots
JB48 and JB56), reacted with sera from 24% of our patients
and has been identified previously as a potential diagnostic
antigen for Bartonella infection (19, 20, 36). However, because
both these cytosolic proteins are highly conserved among bac-
teria, they are unlikely to be useful for Bartonella-specific di-
agnosis. Considering the frequent recognition and the unique
presence of the Vomp and Hbp in Bartonella, these antigens
are likely to be the most useful antigens for diagnosis of B.
quintana infections in humans.
In summary, we established a 2D map of the total membrane
subproteome of B. quintana. We identified 60 unique B. quin-
tana proteins by 2D gel electrophoresis and PMF, including
OMP virulence factors. Using this newly constructed subpro-
teome map, we identified 24 immunodominant antigens after
performing 2D immunoblotting with sera from 21 naturally
infected patients. Our goal was to perform a general screen for
B. quintana antigens that reacted with serum from 24% or
more of the patients, as a prelude to more definitive future
testing of proteins that appear to be candidate diagnostic
and/or vaccine antigens. Additionally, characterization of the
B. quintana immunome demonstrated that the Vomp virulence
factors are frequently recognized by the host immune system,
supporting the hypothesis that anti-Vomp antibodies can stim-
ulate the phase variation that occurs in vivo. The identification
and evaluation of these B. quintana proteins should not only
aid in the development of better diagnostic tests and better
disease prevention but also provide insight into the pathogen-
esis of Bartonella.
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